Scandinavian Cystic Fibrosis Azithromycin Study
Information source: Rigshospitalet, Denmark
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cystic Fibrosis
Intervention: Study medication, azithromycin or placebo (Drug); Azithromycin or placebo tablets (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Rigshospitalet, Denmark Official(s) and/or principal investigator(s): Niels Hoiby, Prof.M.D.DSc, Principal Investigator, Affiliation: Department of Clinical Microbiology, Rigshospitalet
Summary
In patients with Cystic Fibrosis, recurrent airway infection caused by Pseudomonas
aeruginosa ultimately leads to chronic airway infection. The purpose of this study is to
determine whether supplementary low-dose azithromycin to standard inhaled colistin and oral
ciprofloxacin in the treatment of intermittent pseudomonas airway-infection can postpone the
next episode of intermittent pseudomonas airway-infection and prevent development of chronic
airway-infection.
Clinical Details
Official title: Supplementary Oral Azithromycin in Treatment of Intermittent Pseudomonas Aeruginosa Colonization in CF-patients With Inhaled Colistin and Oral Ciprofloxacin; Postponing Next Isolate of Pseudomonas and Prevention of Chronic Infection. A Prospective, Double-blinded, Placebo-controlled Scandinavian Multi-centre Study.
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Primary outcome: Time to next airway-colonization (re-colonization) with Pseudomonas aeruginosa
Secondary outcome: Clinical condition of the patients (height, weight and lung function)Bacteriological examination of Pseudomonas aeruginosa (phenotype, resistance) Genotyping of Pseudomonas aeruginosa using Pulsed Field Gel Electrophoresis (re-infection caused by identical or new strain) Specific, precipitating pseudomonas-antibodies (establishment of chronic infection)
Detailed description:
Cystic Fibrosis is the most common genetic, inherited, deadly disease in caucasians. The
disease is characterized by recurrent airway-infections caused by Pseudomonas aeruginosa,
ultimately leading to chronic airway-infection, which is the main cause of the increased
morbidity and mortality seen in this disease.
P. aeruginosa has the ability to change to mucoid phenotype - producing alginate and growing
in biofilm, which protects the microorganisms from antibiotics and leukocytes. The change in
phenotype is seen as chronic infection is established and eradication becomes impossible.
Treatment with long-term, low-dose azithromycin in chronically infected CF-patients can
improve the clinical condition of the patients. The exact mechanism for this is not known,
but is possibly a combination of anti-inflammatory effects and the ability of azithromycin
to inhibit alginate-production. Inhibition of biofilm-formation leaves the bacteria more
susceptible to the actions of antibiotics and leukocytes.
Prior to establishment of chronic infection, recurrent, intermittent colonization of the
airways with non-mucoid P. aeruginosa is seen. Intermittent infections can be treated using
a combination of antibiotics, thereby postponing the next episode of airway-infection with
P. aeruginosa.
The purpose of this study is to clarify wether supplementary azithromycin in the treatment
of intermittent pseudomonas-infection in CF-patients can lead to further postponement of
next pseudomonas-colonization and maybe prevent development of chronic infection. This is
done in a randomised, double-blinded, placebo-controlled multicentre study.
2 treatments will be compared:
1. Inhaled colistin and oral ciprofloxacin in combination with oral azithromycin
2. Inhaled colistin and oral ciprofloxacin in combination with oral placebo.
The treatment will be given for 3 weeks, and the primary end-point is the time until next
colonization with P. aeruginosa in the airways of the patients, comparing the 2
treatment-groups.
Eligibility
Minimum age: 1 Year.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of Cystic Fibrosis based on genotype and/or positive sweat-test
- Written informed consent based on written and spoken information
- No chronic airway-infections with Gram-negative bacteria
- Fertile, sexually active women must use contraception (p-pills, IUD or other methods
with a similar Pearl-index) when participating in the study
Exclusion Criteria:
- P. aeruginosa in airway secretions obtained less than 3 months prior to inclusion
- Chronic infection of the airways caused by Gram-negative bacteria (Burkholderia
species, Achromobacter xylosoxidans, Pandorea apista or Stenotrophomonas maltophilia)
- Chronic infection of the airways caused by P. aeruginosa (chronic infection is
defined by continuing growth of the microorganism for 6 months and/or an increase in
specific, precipitating antibodies to a level of at least 2)
- Previous infection with a strain of P. aeruginosa resistant to ciprofloxacin or
colistin
- Previous participation in a pseudomonas-vaccination-study
- Patients younger than 1 year
- Pregnant or lactating women, or sexually active women unwilling to use safe
contraception (p-pills, IUD or method with similar Pearl-index) when participating in
the study
- Severe insufficiency of the liver or kidneys as judged by the local investigator
Locations and Contacts
CF-centre Skejby, Skejby Sygehus, Brendstrupgaardsvej 100, Aarhus N 8200, Denmark
CF-centre Copenhagen, Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, Denmark
CF-centre Bergen, Haukeland Universitetssykehus, Bergen 5021, Norway
CF-centre Oslo, Ullevaal Universitetssykehus, Oslo 0407, Norway
CF-centre Göteborg, Drottning Silvias barn- och ungdomssjukhus, Göteborg 416 85, Sweden
CF-centre Lund, Universitetssjukhuset i Lund, Lund 221 85, Sweden
CF-centre Stockholm, Karolinska Universitetssjukhuset, Huddinge, Stockholm 141 86, Sweden
CF-centre Uppsala, Akademiska Barnsjukhuset, Uppsala 751 85, Sweden
Additional Information
Related publications: Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000 Oct;16(4):749-67. Review. Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 2005 Aug;4 Suppl 2:49-54. Review. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991 Sep 21;338(8769):725-6. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002 Sep 28;360(9338):978-84. Gillis RJ, White KG, Choi KH, Wagner VE, Schweizer HP, Iglewski BH. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2005 Sep;49(9):3858-67. Hansen CR, Pressler T, Koch C, Høiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros. 2005 Mar;4(1):35-40. Jaffé A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 1998 Feb 7;351(9100):420. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003 Oct 1;290(13):1749-56. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002 Mar;57(3):212-6. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med. 1995 Dec 29;99(6A):26S-30S.
Starting date: May 2008
Last updated: March 13, 2014
|